<p>Insulet Corporation (NASDAQ:PODD - 獲取免費報告) 的股價在週三的午盤交易中下跌了 3.4%，原因是高盛集團將該股票的目標價從 399.00 美元下調至 375.00 美元。高盛集團目前對該股票維持買入評級。Insulet 的最低交易價格為 305.22 美元，最後交易價格為 298.14 美元。在交易過程中，約有 50,130 股易手，較 742,312 股的日均交易量下降了 93%。該股票之前的收盤價為 308.73 美元。</p>
<ul>
<li>2025 年表現優異的 3 只醫療科技股票</li>
</ul>
<p>其他一些分析師最近也對該公司發佈了報告。傑富瑞金融集團在 8 月 7 日的研究報告中重申了對 Insulet 股票的 “買入” 評級。摩根大通將 Insulet 的目標價從 340.00 美元上調至 415.00 美元，並在 9 月 12 日的研究報告中給予該股票 “超配” 評級。巴克萊將 Insulet 的目標價從 266.00 美元上調至 300.00 美元，並在 8 月 21 日的研究報告中給予該公司 “等權重” 評級。華爾街 Zen 在 8 月 9 日的報告中將 Insulet 的評級從 “持有” 上調至 “買入”。最後，奧本海默在 9 月 8 日的報告中將 Insulet 的目標價從 324.00 美元上調至 365.00 美元，並給予該股票 “跑贏大盤” 評級。十六位股票研究分析師對該股票給予了買入評級，另外兩位分析師給予了持有評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “適度買入”，共識目標價為 345.47 美元。</p>
<p><strong>獲取我們最新的 PODD 股票分析</strong></p>
<h2>Insulet 的內部買賣情況</h2>
<ul>
<li>Insulet 在第一季度業績超預期，成為標準普爾 500 指數的頂級表現者</li>
</ul>
<p>在相關消息中，SVP Laetitia Cousin 在 9 月 8 日的交易中出售了 797 股 Insulet 股票。該股票以 348.81 美元的平均價格出售，總交易額為 278,001.57 美元。交易完成後，該高級副總裁直接持有該公司 3,890 股股票，價值 1,356,870.90 美元。此次交易使其持股減少了 17.00%。該出售在向 SEC 提交的文件中披露，文件可通過此鏈接獲取。此外，SVP Prem Singh 在 9 月 8 日的交易中出售了 687 股 Insulet 股票。該股票以 347.49 美元的平均價格出售，總價值為 238,725.63 美元。出售後，該高級副總裁持有該公司 3,456 股股票，價值約為 1,200,925.44 美元。這代表其持股減少了 16.58%。該出售的披露信息可以在這裏找到。內部人士持有該公司 0.39% 的股票。</p>
<h2>Insulet 的機構交易情況</h2>
<p>對沖基金最近買賣了該公司的股票。Inspire Investing LLC 在第一季度將其在 Insulet 的股份增加了 299.5%。Inspire Investing LLC 現在擁有 4,119 股醫療儀器供應商的股票，價值 1,082,000 美元，此前在該期間購買了 3,088 股。Allspring Global Investments Holdings LLC 在第一季度將其在 Insulet 的持股增加了 55.5%。Allspring Global Investments Holdings LLC 現在擁有 5,229 股醫療儀器供應商的股票，價值 1,376,000 美元，此前在上個季度增加了 1,867 股。高盛集團在第一季度將其在 Insulet 的持股增加了 1.9%。高盛集團現在擁有 579,302 股醫療儀器供應商的股票，價值 152,130,000 美元，此前在上個季度購買了 10,628 股。Gradient Investments LLC 在第二季度購買了 Insulet 的新股份，價值 17,429,000 美元。最後，Vident Advisory LLC 在第一季度獲得了 Insulet 的新股份，價值 216,000 美元。</p>
<h2>Insulet 股票下跌 5.9%</h2>
<ul>
<li>這 5 只被低估的股票準備突破嗎？</li>
</ul>
<p>該公司的市值為 204.5 億美元，市盈率為 88.85，市盈增長比率為 2.58，貝塔值為 1.36。該公司的流動比率為 2.26，速動比率為 1.81，債務股本比率為 0.64。該公司的 50 日移動平均線為 320.07 美元，200 日移動平均線為 297.80 美元。</p>
<p>Insulet (NASDAQ:PODD - 獲取免費報告) 最近在 8 月 7 日發佈了季度財報。該醫療儀器供應商報告本季度每股收益為 1.17 美元，超出市場共識預期的 0.92 美元，超出幅度為 0.25 美元。Insulet 的股本回報率為 23.78%，淨利潤率為 10.01%。該公司本季度的收入為 6.491 億美元，而分析師預期為 6.1231 億美元。在去年同期，該公司每股收益為 0.55 美元。與去年同期相比，該公司的收入增長了 32.9%。Insulet 已將其 2025 財年的每股收益指引設定為每股收益。2025 年第三季度的指引為每股收益。平均而言，股票研究分析師預測 Insulet Corporation 本年度將發佈 3.92 美元的每股收益。</p>
<h2>關於 Insulet</h2>
<p>(獲取免費報告)</p>
<p>Insulet Corporation 開發、製造和銷售用於胰島素依賴型糖尿病患者的胰島素輸送系統。該公司的 Omnipod 平台包括 Omnipod 5 自動胰島素輸送系統（Omnipod 5），該系統在 Pod 中嵌入了專有的 AID 算法，可以通過無線藍牙通信與第三方連續血糖監測儀集成以獲取血糖值；Omnipod DASH 具有藍牙功能的 Pod，由類似智能手機的個人糖尿病管理器控制，配備彩色觸摸屏用户界面；以及 Omnipod GO，一種獨立的可穿戴胰島素輸送系統，提供 72 小時的固定速率連續速效胰島素。</p>
<h2>精選文章</h2>
<ul>
<li>我們更看好的五隻股票超過 Insulet</li>
<li>現在可以購買的三隻沃倫·巴菲特股票</li>
<li>直覺外科是否是醫療行業疲軟中的隱藏贏家？</li>
<li>投資者如何從盤後交易中獲益</li>
<li>鋰美洲股票上週暴漲——原因在這裏</li>
<li>期權交易 - 理解行使價格</li>
<li>為什麼亞馬遜最新的升級可能是其最重要的一次</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Insulet 嗎？</h2>
<p>在考慮 Insulet 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Insulet 並不在名單上。</p>
<p>雖然 Insulet 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

PODD

<p>Insulet Corporation（納斯達克代碼：PODD）在高盛將其目標股價從 399 美元下調至 375 美元的消息後，股價下跌了 3.4%，同時維持買入評級。該股最低交易價為 305.22 美元，收盤價為 298.14 美元，交易量較平均水平下降了 93%。儘管如此，其他分析師仍然給予了積極評級，普遍評級為 “適度買入”，目標價為 345.47 美元。Insulet 最近的財報顯示出顯著的收入增長，超出預期</p>

<p>Insulet Corporation (NASDAQ:PODD - Get Free Report)'s share price was down 3.4% during mid-day trading on Wednesday after The Goldman Sachs Group lowered their price target on the stock from $399.00 to $375.00. The Goldman Sachs Group currently has a buy rating on the stock. Insulet traded as low as $305.22 and last traded at $298.14. Approximately 50,130 shares changed hands during trading, a decline of 93% from the average daily volume of 742,312 shares. The stock had previously closed at $308.73.</p>
<div class="lb-trans"><p>Insulet Corporation (NASDAQ:PODD - 獲取免費報告) 的股價在週三的午盤交易中下跌了 3.4%，原因是高盛集團將該股票的目標價從 399.00 美元下調至 375.00 美元。高盛集團目前對該股票維持買入評級。Insulet 的最低交易價格為 305.22 美元，最後交易價格為 298.14 美元。在交易過程中，約有 50,130 股易手，較 742,312 股的日均交易量下降了 93%。該股票之前的收盤價為 308.73 美元。</p>
</div><ul>
<li>3 Medical Technology Stocks Outperforming in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年表現優異的 3 只醫療科技股票</li>
</ul>
</div><p>A number of other analysts have also recently issued reports on the company. Jefferies Financial Group reissued a &#34;buy&#34; rating on shares of Insulet in a research report on Thursday, August 7th. JPMorgan Chase &amp; Co. increased their target price on shares of Insulet from $340.00 to $415.00 and gave the stock an &#34;overweight&#34; rating in a research note on Friday, September 12th. Barclays upped their price objective on Insulet from $266.00 to $300.00 and gave the company an &#34;equal weight&#34; rating in a research note on Thursday, August 21st. Wall Street Zen raised Insulet from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Saturday, August 9th. Finally, Oppenheimer increased their price target on Insulet from $324.00 to $365.00 and gave the stock an &#34;outperform&#34; rating in a report on Monday, September 8th. Sixteen equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $345.47.</p>
<div class="lb-trans"><p>其他一些分析師最近也對該公司發佈了報告。傑富瑞金融集團在 8 月 7 日的研究報告中重申了對 Insulet 股票的 “買入” 評級。摩根大通將 Insulet 的目標價從 340.00 美元上調至 415.00 美元，並在 9 月 12 日的研究報告中給予該股票 “超配” 評級。巴克萊將 Insulet 的目標價從 266.00 美元上調至 300.00 美元，並在 8 月 21 日的研究報告中給予該公司 “等權重” 評級。華爾街 Zen 在 8 月 9 日的報告中將 Insulet 的評級從 “持有” 上調至 “買入”。最後，奧本海默在 9 月 8 日的報告中將 Insulet 的目標價從 324.00 美元上調至 365.00 美元，並給予該股票 “跑贏大盤” 評級。十六位股票研究分析師對該股票給予了買入評級，另外兩位分析師給予了持有評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “適度買入”，共識目標價為 345.47 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on PODD</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 PODD 股票分析</strong></p>
</div><h2>Insider Buying and Selling at Insulet</h2>
<div class="lb-trans"><h2>Insulet 的內部買賣情況</h2>
</div><ul>
<li>Insulet Surges on Q1 Beat, Emerges as a Top S&amp;P 500 Performer</li>
</ul>
<div class="lb-trans"><ul>
<li>Insulet 在第一季度業績超預期，成為標準普爾 500 指數的頂級表現者</li>
</ul>
</div><p>In related news, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the transaction, the senior vice president directly owned 3,890 shares in the company, valued at $1,356,870.90. The trade was a 17.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Prem Singh sold 687 shares of Insulet stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president owned 3,456 shares of the company's stock, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.39% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，SVP Laetitia Cousin 在 9 月 8 日的交易中出售了 797 股 Insulet 股票。該股票以 348.81 美元的平均價格出售，總交易額為 278,001.57 美元。交易完成後，該高級副總裁直接持有該公司 3,890 股股票，價值 1,356,870.90 美元。此次交易使其持股減少了 17.00%。該出售在向 SEC 提交的文件中披露，文件可通過此鏈接獲取。此外，SVP Prem Singh 在 9 月 8 日的交易中出售了 687 股 Insulet 股票。該股票以 347.49 美元的平均價格出售，總價值為 238,725.63 美元。出售後，該高級副總裁持有該公司 3,456 股股票，價值約為 1,200,925.44 美元。這代表其持股減少了 16.58%。該出售的披露信息可以在這裏找到。內部人士持有該公司 0.39% 的股票。</p>
</div><h2>Institutional Trading of Insulet</h2>
<div class="lb-trans"><h2>Insulet 的機構交易情況</h2>
</div><p>Hedge funds have recently bought and sold shares of the company. Inspire Investing LLC lifted its stake in shares of Insulet by 299.5% during the 1st quarter. Inspire Investing LLC now owns 4,119 shares of the medical instruments supplier's stock worth $1,082,000 after purchasing an additional 3,088 shares during the period. Allspring Global Investments Holdings LLC boosted its position in shares of Insulet by 55.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 5,229 shares of the medical instruments supplier's stock worth $1,376,000 after acquiring an additional 1,867 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Insulet by 1.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 579,302 shares of the medical instruments supplier's stock valued at $152,130,000 after purchasing an additional 10,628 shares during the last quarter. Gradient Investments LLC purchased a new stake in shares of Insulet during the 2nd quarter valued at $17,429,000. Finally, Vident Advisory LLC acquired a new stake in shares of Insulet during the 1st quarter worth $216,000.</p>
<div class="lb-trans"><p>對沖基金最近買賣了該公司的股票。Inspire Investing LLC 在第一季度將其在 Insulet 的股份增加了 299.5%。Inspire Investing LLC 現在擁有 4,119 股醫療儀器供應商的股票，價值 1,082,000 美元，此前在該期間購買了 3,088 股。Allspring Global Investments Holdings LLC 在第一季度將其在 Insulet 的持股增加了 55.5%。Allspring Global Investments Holdings LLC 現在擁有 5,229 股醫療儀器供應商的股票，價值 1,376,000 美元，此前在上個季度增加了 1,867 股。高盛集團在第一季度將其在 Insulet 的持股增加了 1.9%。高盛集團現在擁有 579,302 股醫療儀器供應商的股票，價值 152,130,000 美元，此前在上個季度購買了 10,628 股。Gradient Investments LLC 在第二季度購買了 Insulet 的新股份，價值 17,429,000 美元。最後，Vident Advisory LLC 在第一季度獲得了 Insulet 的新股份，價值 216,000 美元。</p>
</div><h2>Insulet Stock Down 5.9%</h2>
<div class="lb-trans"><h2>Insulet 股票下跌 5.9%</h2>
</div><ul>
<li>Are These 5 Undervalued Stocks Ready to Break Out?</li>
</ul>
<div class="lb-trans"><ul>
<li>這 5 只被低估的股票準備突破嗎？</li>
</ul>
</div><p>The firm has a market capitalization of $20.45 billion, a PE ratio of 88.85, a price-to-earnings-growth ratio of 2.58 and a beta of 1.36. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. The firm has a 50-day moving average of $320.07 and a two-hundred day moving average of $297.80.</p>
<div class="lb-trans"><p>該公司的市值為 204.5 億美元，市盈率為 88.85，市盈增長比率為 2.58，貝塔值為 1.36。該公司的流動比率為 2.26，速動比率為 1.81，債務股本比率為 0.64。該公司的 50 日移動平均線為 320.07 美元，200 日移動平均線為 297.80 美元。</p>
</div><p>Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business had revenue of $649.10 million for the quarter, compared to analyst estimates of $612.31 million. During the same period in the previous year, the company posted $0.55 EPS. The company's revenue was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities research analysts forecast that Insulet Corporation will post 3.92 EPS for the current year.</p>
<div class="lb-trans"><p>Insulet (NASDAQ:PODD - 獲取免費報告) 最近在 8 月 7 日發佈了季度財報。該醫療儀器供應商報告本季度每股收益為 1.17 美元，超出市場共識預期的 0.92 美元，超出幅度為 0.25 美元。Insulet 的股本回報率為 23.78%，淨利潤率為 10.01%。該公司本季度的收入為 6.491 億美元，而分析師預期為 6.1231 億美元。在去年同期，該公司每股收益為 0.55 美元。與去年同期相比，該公司的收入增長了 32.9%。Insulet 已將其 2025 財年的每股收益指引設定為每股收益。2025 年第三季度的指引為每股收益。平均而言，股票研究分析師預測 Insulet Corporation 本年度將發佈 3.92 美元的每股收益。</p>
</div><h2>About Insulet</h2>
<div class="lb-trans"><h2>關於 Insulet</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.</p>
<div class="lb-trans"><p>Insulet Corporation 開發、製造和銷售用於胰島素依賴型糖尿病患者的胰島素輸送系統。該公司的 Omnipod 平台包括 Omnipod 5 自動胰島素輸送系統（Omnipod 5），該系統在 Pod 中嵌入了專有的 AID 算法，可以通過無線藍牙通信與第三方連續血糖監測儀集成以獲取血糖值；Omnipod DASH 具有藍牙功能的 Pod，由類似智能手機的個人糖尿病管理器控制，配備彩色觸摸屏用户界面；以及 Omnipod GO，一種獨立的可穿戴胰島素輸送系統，提供 72 小時的固定速率連續速效胰島素。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Insulet</li>
<li>3 Warren Buffett Stocks to Buy Now</li>
<li>Is Intuitive Surgical the Hidden Winner in Healthcare’s Weakness?</li>
<li>How Can Investors Benefit From After-Hours Trading</li>
<li>Lithium Americas Stock Exploded Last Week—Here’s Why</li>
<li>Options Trading - Understanding Strike Price</li>
<li>Why Amazon’s Latest Upgrade Might Be Its Most Important Yet</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 Insulet</li>
<li>現在可以購買的三隻沃倫·巴菲特股票</li>
<li>直覺外科是否是醫療行業疲軟中的隱藏贏家？</li>
<li>投資者如何從盤後交易中獲益</li>
<li>鋰美洲股票上週暴漲——原因在這裏</li>
<li>期權交易 - 理解行使價格</li>
<li>為什麼亞馬遜最新的升級可能是其最重要的一次</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Insulet Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Insulet 嗎？</h2>
</div><p>Before you consider Insulet, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Insulet 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Insulet 並不在名單上。</p>
</div><p>While Insulet currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Insulet 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Insulet（NASDAQ:PODD）股價在分析師下調評級後下跌了 3.4%